TPG GP A, LLC

October 10, 2026

Keybanc Raises LifeStance Health Price Target to $15. Keybanc maintained an Overweight rating on LifeStance Health and raised its price target to $15. This follows the company's recent Q2 2026 earnings call. The stock is currently trading near the middle of its 52-week range, with an average analyst target of $14.40.

September 30, 2026

CeriBell Gets FDA Clearance for New EEG Analysis Tools. CeriBell Inc. announced that the FDA has granted 510(k) clearance for its quantitative EEG trending and amplitude-integrated EEG analysis features. This regulatory approval allows the company to market these specific diagnostic tools, which may support its clinical utility and product roadmap. The stock is currently trading within its 52-week range, with analyst targets averaging $28.00.

October 7, 2026

Odyssey Therapeutics to Present OD-001 Data at UEG Week 2026. Odyssey Therapeutics announced that it will present additional Phase 2a induction data for its drug OD-001 in ulcerative colitis at the UEG Week 2026 conference. This upcoming presentation provides new clinical information on the company's lead candidate. The stock is currently trading near its 52-week low, with an average analyst target price of $35.75.

October 16, 2026

Sionna Shares Fall 37.6% Over 4 Weeks, Trend Reversal Possible. Sionna Therapeutics shares fell 37.6% over the past four weeks. The drop has pushed the stock into a low RSI zone of 23.4, suggesting it may be oversold. The price is near a key support level at $5.71, which has been tested 20 times. Analysts see a potential trend reversal, but the stock remains far below its 52‑week high of $54.97.

October 16, 2026

BETA Technologies Tests Electric Flights in Utah, Analyst Coverage Added. BETA Technologies conducted electric flight tests in Utah as part of its training push. The company has recently attracted new analyst coverage, with Barclays assigning an overweight rating and a $35 price target. The latest tests support the company’s focus on electric propulsion, while the 52‑week range shows a broad upside potential. Current technical signals show the stock near a 200‑day moving‑average touch and an RSI of 39.9.

September 25, 2026

SeekingAlpha article on DiviDog buys does not mention TRTX. A SeekingAlpha piece discussed 18 'safer' DiviDog buys, but it does not mention TRTX. Therefore, no direct impact on TRTX is indicated. TRTX remains in a low RSI zone and near its 52‑week low, with a high dividend yield.

October 16, 2026

Life Time Opens New Lakewood Ranch Club and Hosts Pickleball Event. Life Time Group Holdings opened a new 180,000-square-foot athletic country club in Lakewood Ranch on October 12. The company also announced the return of its Classic National Pickleball Tournament, featuring its largest prize purse to date. These developments highlight the company's ongoing expansion and focus on community engagement.

October 6, 2026

ServiceTitan Shares Rise After CFO Sale and Ramp Partnership. ServiceTitan shares moved higher after the company announced a partnership with Ramp to automate contractor financial workflows using AI tools. The move comes as CFO David Sherry sold 23,245 shares for about $1.3 million, a transaction that did not dampen market interest. Meanwhile, crypto‑linked stocks are trading higher following a recent decline, adding to broader market momentum.

October 13, 2026

NRDY Q2 2026 Earnings Conference Call Held. Nerdy Inc. conducted its Q2 2026 earnings conference call. Management reviewed the latest financial results and provided guidance for the coming period. The discussion offers investors insight into the company's performance as the stock trades with a low RSI, suggesting oversold momentum.

October 13, 2026

BCAX flagged as potentially overvalued on book value. A recent analysis suggests Bicara Therapeutics stock may be overvalued when compared to its book value. This valuation concern is notable given that the stock is currently trading near its 52-week low and has an RSI of 30.1, indicating it is in oversold territory. While the average analyst target is $35.50, the wide range of estimates reflects significant uncertainty about the company's future performance.

October 11, 2026

Cushman & Wakefield Receives S&P BB Rating Upgrade. Cushman & Wakefield was upgraded to a ‘BB’ rating by S&P Global Ratings, citing progress on leverage. The company also faces increased scrutiny from Chicago office tenants and rising industrial build costs that could impact its portfolio. Additionally, a grocery‑anchored joint venture expansion with Phillips Edison may broaden its commercial footprint.

October 4, 2026

Piper Sandler cuts Nextpower target to $110, maintains Overweight. Piper Sandler lowered its price target for Nextpower to $110 while keeping an Overweight rating. This move comes as the stock recently saw significant gains alongside other energy-related names. The new target is below the current average analyst estimate of $138.96, reflecting a more conservative outlook from this specific firm.

October 3, 2026

SLE Included in Communication Services Movers List. Super League Enterprise was highlighted in a Benzinga report listing communication services stocks with notable intraday movement on Monday. The stock is currently trading near its 52-week low, a context that may explain its inclusion in a list of volatile movers. Technical indicators show the price is near support levels, reflecting the recent volatility captured in the news.

October 12, 2026

Progyny (PGNY) shares rise over 6% amid record sales pace. Shares of Progyny jumped about 6% after the company reported a selling season that is pacing toward a record level. Analysts noted the move while also comparing the stock’s valuation to peers such as CRL. The price action comes as the stock trades with an RSI near 61 and holds above a support level around $25.40. The news adds to recent discussion about potential upside, though the stock remains below its 52‑week high.

October 8, 2026

AMRX Gains Fair Value Bump After Analyst Support for New Launches. Analysts have raised AMRX's fair value after backing new product launches, lifting the stock's target range. The company is listed among low‑volatility stocks that still have open questions for investors. The move comes as the shares trade near the middle of their 52‑week range and around the 53.3 RSI level.

October 12, 2026

TRVI releases Q2 2026 earnings and makes Raymond James top health list. Trevi Therapeutics held its Q2 2026 earnings call, sharing the latest financial and operational results. In a separate note, Raymond James analysts listed the stock among their top four healthcare picks. The earnings discussion and analyst endorsement may draw additional attention to the company. The shares are trading close to the upper end of their 52‑week range.